These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24519993)

  • 1. A photochromic agonist for μ-opioid receptors.
    Schönberger M; Trauner D
    Angew Chem Int Ed Engl; 2014 Mar; 53(12):3264-7. PubMed ID: 24519993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Red-Shifting Azobenzene Photoswitches for in Vivo Use.
    Dong M; Babalhavaeji A; Samanta S; Beharry AA; Woolley GA
    Acc Chem Res; 2015 Oct; 48(10):2662-70. PubMed ID: 26415024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deuteration as a General Strategy to Enhance Azobenzene-Based Photopharmacology.
    Roßmann K; Gonzalez-Hernandez AJ; Bhuyan R; Schattenberg C; Sun H; Börjesson K; Levitz J; Broichhagen J
    Angew Chem Int Ed Engl; 2024 Sep; 63(39):e202408300. PubMed ID: 38897926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Optimized Glutamate Receptor Photoswitch with Sensitized Azobenzene Isomerization.
    Gascón-Moya M; Pejoan A; Izquierdo-Serra M; Pittolo S; Cabré G; Hernando J; Alibés R; Gorostiza P; Busqué F
    J Org Chem; 2015 Oct; 80(20):9915-25. PubMed ID: 26414427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photochemical approaches to vision restoration.
    Van Gelder RN
    Vision Res; 2015 Jun; 111(Pt B):134-41. PubMed ID: 25680758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of Redshifted Azobenzene Photoswitches by Late-Stage Functionalization.
    Konrad DB; Frank JA; Trauner D
    Chemistry; 2016 Mar; 22(13):4364-8. PubMed ID: 26889884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary events in dim light vision: a chemical and spectroscopic approach toward understanding protein/chromophore interactions in rhodopsin.
    Fishkin N; Berova N; Nakanishi K
    Chem Rec; 2004; 4(2):120-35. PubMed ID: 15073879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Photoswitchable Tethered Ligands that Target the μ-Opioid Receptor.
    Lahmy R; Hübner H; Lachmann D; Gmeiner P; König B
    ChemMedChem; 2023 Dec; 18(23):e202300228. PubMed ID: 37817331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of G(i)alpha2-protein in opioid tolerance and mu-opioid receptor downregulation in vivo.
    Yoburn BC; Gomes BA; Rajashekara V; Patel C; Patel M
    Synapse; 2003 Feb; 47(2):109-16. PubMed ID: 12454948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of gonadal hormones on opioid receptor protein density in arthritic rats.
    Kren MC; Haller VL; Welch SP
    Eur J Pharmacol; 2008 Jan; 578(2-3):177-84. PubMed ID: 18054782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective interactions of spinophilin with the C-terminal domains of the δ- and μ-opioid receptors and G proteins differentially modulate opioid receptor signaling.
    Fourla DD; Papakonstantinou MP; Vrana SM; Georgoussi Z
    Cell Signal; 2012 Dec; 24(12):2315-28. PubMed ID: 22922354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective interactions between G protein subunits and RGS4 with the C-terminal domains of the mu- and delta-opioid receptors regulate opioid receptor signaling.
    Georgoussi Z; Leontiadis L; Mazarakou G; Merkouris M; Hyde K; Hamm H
    Cell Signal; 2006 Jun; 18(6):771-82. PubMed ID: 16120478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties.
    Valenzano KJ; Miller W; Chen Z; Shan S; Crumley G; Victory SF; Davies E; Huang JC; Allie N; Nolan SJ; Rotshteyn Y; Kyle DJ; Broglé K
    J Pharmacol Exp Ther; 2004 Aug; 310(2):783-92. PubMed ID: 15054115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A supra-photoswitch involving sandwiched DNA base pairs and azobenzenes for light-driven nanostructures and nanodevices.
    Liang X; Mochizuki T; Asanuma H
    Small; 2009 Aug; 5(15):1761-8. PubMed ID: 19572326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutively active μ-opioid receptors.
    Connor M; Traynor J
    Methods Enzymol; 2010; 484():445-69. PubMed ID: 21036245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of peripheral μ-opioid analgesia by σ1 receptors.
    Sánchez-Fernández C; Montilla-García Á; González-Cano R; Nieto FR; Romero L; Artacho-Cordón A; Montes R; Fernández-Pastor B; Merlos M; Baeyens JM; Entrena JM; Cobos EJ
    J Pharmacol Exp Ther; 2014 Jan; 348(1):32-45. PubMed ID: 24155346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. μ-Opioid and 5-HT1A receptors heterodimerize and show signalling crosstalk via G protein and MAP-kinase pathways.
    Cussac D; Rauly-Lestienne I; Heusler P; Finana F; Cathala C; Bernois S; De Vries L
    Cell Signal; 2012 Aug; 24(8):1648-57. PubMed ID: 22560877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute and chronic fentanyl administration causes hyperalgesia independently of opioid receptor activity in mice.
    Waxman AR; Arout C; Caldwell M; Dahan A; Kest B
    Neurosci Lett; 2009 Oct; 462(1):68-72. PubMed ID: 19559072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of TRPV1-expressing sensory neurons reduces spinal mu opioid receptors but paradoxically potentiates opioid analgesia.
    Chen SR; Pan HL
    J Neurophysiol; 2006 May; 95(5):3086-96. PubMed ID: 16467418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
    Alt A; McFadyen IJ; Fan CD; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2001 Jul; 298(1):116-21. PubMed ID: 11408532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.